23:26 , Aug 23, 2019 |  BC Extra  |  Politics & Policy

Coalition forms to push changes in antimicrobial payment system

To ensure that companies are incentivized to develop new antibiotics, a coalition of industry leaders has launched Working to Fight AMR to raise public awareness of antimicrobial resistance and encourage grassroots action to push forward...
22:14 , Aug 16, 2019 |  BC Extra  |  Company News

Ahead of FDA decisions on one antibiotic, Nabriva plans resubmission of another

As it awaits FDA's decisions on twin NDAs for lefamulin, Nabriva said it plans to resubmit an NDA early next quarter for another one of its antibiotics following a complete response letter this year. Nabriva...
00:44 , Aug 6, 2019 |  BC Extra  |  Politics & Policy

How CMS plans to retool payments for antibiotics

CMS updated its payment system last week to make it easier for antibiotic companies to turn a profit, but the changes improve an already-established pathway rather than implementing an innovative subscription-based model as called for...
00:21 , Aug 6, 2019 |  BC Extra  |  Company News

Management tracks: Allogene snags Adaptimmune's Amado; plus Foundation Medicine, CymaBay and more

CAR T therapy company Allogene Therapeutics Inc . (NASDAQ:ALLO) hired Rafael G. Amado as EVP of R&D and CMO, effective Sept. 3. He was president of R&D at Adaptimmune Therapeutics plc (NASDAQ:ADAP). Allogene Executive Chairman...
00:51 , Aug 2, 2019 |  BC Extra  |  Company News

Aug. 1 Management tracks: R&D chief leaving Adaptimmune; plus Frontier Medicines builds out team and more

Adrian Rawcliffe, the incoming CEO of Adaptimmune Therapeutics plc (NASDAQ:ADAP), said Rafael Amado is leaving the T cell therapy company as president of R&D, effective Aug. 12, to pursue other opportunities. Rawcliffe also announced the...
02:33 , Jul 13, 2019 |  BioCentury  |  Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
20:37 , Jun 7, 2019 |  BC Extra  |  Company News

June 7 Company Quick Takes: Expanded label for PTC’s DMD drug; plus Achaogen, ICER on migraine and Nucala

PTC’s DMD drug approved in patients ages 2-5  FDA approved an sNDA for Emflaza deflazacort from PTC Therapeutics Inc. (NASDAQ:PTCT) to treat Duchenne muscular dystrophy in patients ages 2-5. The drug was first approved in...
23:04 , Jun 6, 2019 |  BC Extra  |  Politics & Policy

New antibiotic treatments focus of reintroduced Senate bill

A bill that would advance research into new treatments for drug-resistant infections, the DISARM Act of 2019, was reintroduced in the Senate this week. The Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act (...
23:45 , Apr 16, 2019 |  BC Extra  |  Company News

Achaogen files for bankruptcy amid continued headwinds for antibiotic developers

Following regulatory headwinds and what it called very limited uptake of its sole marketed antibiotic, Achaogen filed for Chapter 11 bankruptcy late Monday. It is one of several antibiotic companies that have lost over half...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...